Clinical Trial Update: Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty Patients [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial studied basiliximab (Simulect) for preventing rejection in high-risk keratoplasty patients; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Transplantation

Drugs mentioned

• Simulect (Basiliximab)

Snippet

Sponsor: University Hospital Freiburg | Conditions: Corneal Transplantation | Phase 2 | Status: COMPLETED